Eighth International Mesothelioma Interest Group

Oncogene

Volumn 26, Issue 49, 2007, Pages 6959-6967

  Carbone, M ^a   Albelda, S M ^b   Broaddus, V C ^c   Flores, R M ^d   Hillerdal, G ^e   Jaurand, M C ^f,g   Kjaerheim, K ^h   Pass, H I ⁱ   Robinson, B ^j   Tsao, A ^k  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f FONDATION JEAN DAUSSET CEPH   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h CANCER REGISTRY OF NORWAY   (Norway)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Asbestos; Gene environment; Mesothelioma; SV40

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ASBESTOS; BETA INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DENDRITIC CELL VACCINE; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; MESOTHELIN ANTIBODY; NAVELBINE; PEMETREXED; POLIOMYELITIS VACCINE; PROTEASOME INHIBITOR; PROTEIN ANTIBODY; PSEUDOMONAS EXOTOXIN; RANPIRNASE; SM 16; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINOFLUNINE; VORINOSTAT;

ABDOMINAL PAIN; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENE THERAPY; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DECORTICATION; DRUG CONTAMINATION; DRUG MECHANISM; ECONOMIC ASPECT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FATIGUE; GENE INTERACTION; HAND FOOT SYNDROME; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH HAZARD; HEALTH INSURANCE; HUMAN; INJECTION SITE REACTION; LAW SUIT; LUNG RESECTION; MEDICAL EXPERT; MESOTHELIOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; PHYSICIAN; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; PUBLIC FIGURE; PUBLIC HEALTH PROBLEM; REVIEW; SCIENTIST; SERODIAGNOSIS; SIMIAN VIRUS 40; TRADE UNION; TREATMENT RESPONSE; UNITED STATES; UREMIA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 35548948105     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210515     Document Type: Review

References (23)

1. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K et al. (2005). A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65: 8090-8095.
2. Bookchin D, Schumacher J. (2004). The Virus and the Vaccine. St Martin Press, New York, NY, pp 287-367.
3. Broaddus VC, Dansen TB, Abayasiriwardana KS, Wilson SM, Finch AF, Swigart LB et al. (2005). Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem 280: 12486-12493.
4. Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L et al. (2005). SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 65: 5256-5262.
5. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI et al. (2007). A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 7: 147-154.
6. Cristaudo A, Foddis R, Vivaldi A, Buselli R, Gattini V, Guglielmi G et al. (2005). SV40 enhances the risk of malignant mesohelioma among people exposed to asbestos: a molecular epidemiological case-control study. Cancer Res 65: 3049-3052.
7. Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakov K et al. (2005). Some oral poliovirus vaccines were contaminated with infectious simian virus 40 after 1961. Cancer Res 65: 10273-10279.
8. Gazdar AF, Butel JS, Carbone M. (2002). SV40 and human tumors: myth, association or causality? Nat Rev Cancer 2: 957-964.
9. Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN, Yeap BY et al. (2005). Validation of genomic-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11: 4406-4414.
10. Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z et al. (2005). A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 33: 541-548.
11. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P et al. (2006). Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103: 14128-14133.
12. Lagnese JA. (2005). Economic aspects of mesothelioma. In: Pass HI, Vogelzang NJ, Carbone M (eds). Malignant Mesothelioma. Springer: New York, NY, pp 821-832.
13. Leconte C, Andujar P, Renier A, Kheueang L, Abramovski V, Mellottee L et al. (2005). Similar tumor suppressor profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 4: 1862-1869.
14. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K et al. (2006). Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66: 2970-2979.
15. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. (2004). Evidence against a role for SV40 infection in human mesotheliomas and high risk of false positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364: 1157-1166.
16. Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY et al. (2005). Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer 117: 326-332.
17. Pass H, Lott D, Lonardo F, Harbut M, Zhandong L, Tang N et al. (2005). Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels. N Engl J Med 353: 1564-1573.
18. Pietruska JR, Kane AB. (2007). SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 67: 3637-3645.
19. Robinson C, van Bruggen I, Segal A, Dunham N, Sherwood A, Koentgen F et al. (2006). A novel SV40 Tag transgenic model of asbestos-induced mesothelioma: malignant transformation is dose-dependent. Cancer Res 66: 10786-10794.
20. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N et al. (2003). Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616.
21. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Fesik SW. (2006). A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66: 8731-8739.
22. Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K et al. (1998). A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesothelioma. Cancer Res 58: 4505-4509.
23. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al. (2006). TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103: 10397-10402.